Praluent (Sanofi-Aventis U.S. LLC)


Welcome to the PulseAid listing for the Praluent drug offered from Sanofi-Aventis U.S. LLC. This PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Sanofi-Aventis U.S. LLC
NON-PROPRIETARY NAME: alirocumab
SUBSTANCE NAME: ALIROCUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [Chemical/Ingredient]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2015-07-24
END MARKETING DATE: 0000-00-00


Praluent HUMAN PRESCRIPTION DRUG Details:

Item DescriptionPraluent from Sanofi-Aventis U.S. LLC
LABELER NAME: Sanofi-Aventis U.S. LLC
DEA SCHEDULE:
ACTIVE STRENGTH: 75(mg/mL)
START MARKETING DATE: 2015-07-24
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0024-5901_27748799-89b9-4496-bbba-2c2f43889eb9
PRODUCT NDC: 0024-5901
APPLICATION NUMBER: BLA125559

Other ALIROCUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Sanofi-Aventis U.S. LLCPraluent